Abstract
Background: This study aimed to assess the influence of hypokalemia on mortality among hospitalized patients diagnosed with COVID-19 pneumonia.
Methods: A cohort of 300 patients aged>18 diagnosed with COVID-19 pneumonia were included in this study. Demographic data, symptoms, comorbidities, medications, duration of hospitalization, and blood potassium levels were recorded, and hypokalemia was defined as having at least three potassium values below 3.5 mmol/L within the first five days of hospitalization. The study investigated whether hypokalemia serves as a risk factor for mortality in COVID-19 patients.
Results: Among the 300 patients, 57 (19%) were identified with hypokalemia. Patients with hypokalemia were older compared to those without this disturbance (P=0.012). No significant correlation was found between hypokalemia and the presence of diabetes mellitus (P=0.999), hypertension (P=0.193), or cardiovascular disease (P=0.781). However, patients with hypokalemia had a higher usage rate of diuretics (P=0.035). The use of corticosteroids, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, insulin, beta-2 agonists, beta-blockers, antipsychotic drugs, and digoxin was similar between patients with and without hypokalemia (P>0.05). Hypokalemia was associated with a 4.79-fold increase in mortality (P=0.003), and each additional day of hospitalization increased mortality by 1.14 times (P<0.001).
Conclusion: Advanced age and diuretic usage could elevate the risk of hypokalemia in COVID-19 patients. Prolonged hospital stays and higher mortality rates among patients with hypokalemia suggest a need for the careful management of electrolyte imbalances.